← All trials
NCT03228550
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 26, 2017
- Primary completion
- Dec 31, 2017
- Completion date
- Oct 1, 2018
- First posted
- —
- Last posted
- —
- Enrollment
- 100
- Arms / groups
- 4 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Bournemouth UniversityLead sponsor
- Bournemouth UniversityReponsible party - principal investigator
- Bournemouth UniversityOverall official - principal investigator
- Bournemouth UniversityStudy director
- Efamol LtdCollaborator
- Sylvia Waddilove FoundationCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.